Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives $14.29 Consensus Target Price from Brokerages

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has been assigned a consensus recommendation of “Moderate Buy” from the eight brokerages that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, six have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $14.2857.

Several equities research analysts have commented on KPTI shares. Piper Sandler restated an “overweight” rating and issued a $8.00 price target (down from $12.00) on shares of Karyopharm Therapeutics in a research note on Monday, March 30th. Weiss Ratings restated a “sell (d-)” rating on shares of Karyopharm Therapeutics in a research note on Monday, December 29th. Robert W. Baird dropped their price target on shares of Karyopharm Therapeutics from $21.00 to $15.00 and set an “outperform” rating on the stock in a research note on Wednesday, March 25th. HC Wainwright dropped their price target on shares of Karyopharm Therapeutics from $15.00 to $8.00 and set a “buy” rating on the stock in a research note on Wednesday, March 25th. Finally, Cantor Fitzgerald initiated coverage on shares of Karyopharm Therapeutics in a research note on Thursday, February 5th. They issued an “overweight” rating on the stock.

Karyopharm Therapeutics Trading Up 14.1%

Shares of NASDAQ:KPTI opened at $7.21 on Friday. The firm’s 50 day moving average is $7.65 and its two-hundred day moving average is $6.82. Karyopharm Therapeutics has a 52 week low of $3.65 and a 52 week high of $10.99. The firm has a market capitalization of $132.26 million, a P/E ratio of -0.43 and a beta of 0.40.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings results on Friday, February 13th. The company reported ($2.23) EPS for the quarter, beating the consensus estimate of ($2.26) by $0.03. The firm had revenue of $34.08 million during the quarter, compared to analyst estimates of $33.16 million. Analysts predict that Karyopharm Therapeutics will post -0.71 EPS for the current year.

Institutional Investors Weigh In On Karyopharm Therapeutics

A number of institutional investors have recently added to or reduced their stakes in KPTI. XTX Topco Ltd acquired a new stake in Karyopharm Therapeutics in the second quarter worth approximately $56,000. Baird Financial Group Inc. acquired a new stake in Karyopharm Therapeutics in the second quarter worth approximately $45,000. Bank of America Corp DE lifted its position in Karyopharm Therapeutics by 26.8% in the second quarter. Bank of America Corp DE now owns 168,534 shares of the company’s stock worth $726,000 after purchasing an additional 35,626 shares during the period. Bridgeway Capital Management LLC acquired a new stake in Karyopharm Therapeutics in the second quarter worth approximately $163,000. Finally, ADAR1 Capital Management LLC acquired a new stake in Karyopharm Therapeutics in the third quarter worth approximately $164,000. 66.44% of the stock is currently owned by institutional investors and hedge funds.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.